Freedom of Information on a copy of the table and column names of the database used to store data from users of the Coronavirus Yellow Card reporting site (FOI 22/458)
Published 1 June 2022
© Crown copyright 2022
This publication is licensed under the terms of the Open Government Licence v3.0 except where otherwise stated. To view this licence, visit nationalarchives.gov.uk/doc/open-government-licence/version/3 or write to the Information Policy Team, The National Archives, Kew, London TW9 4DU, or email: psi@nationalarchives.gov.uk.
Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned.
This publication is available at https://www.gov.uk/government/publications/freedom-of-information-responses-from-the-mhra-week-commencing-7-march-2022/freedom-of-information-on-a-copy-of-the-table-and-column-names-of-the-database-used-to-store-data-from-users-of-the-coronavirus-yellow-card-reporting
FOI 22/458
9th March 2022
Dear
Thank you for your email dated 10th February 2022 where you requested a copy of the table and column names of the database used to store data from users of the Coronavirus Yellow Card reporting site
Reports of all suspected adverse drug reactions to medicines and vaccines are stored on the MHRA’s purpose-built pharmacovigilance database, Sentinel. The Sentinel database includes reports related to medicines and vaccines used in the treatment of Coronavirus received from the Coronavirus Yellow Card reporting site.
Further to your request please find attached a list of the database table and column names from the Sentinel database. The extract provides a list of all data fields in the Sentinel database as of the 7 March 2022.
I hope the information provided is helpful, but if you are dissatisfied with the handling of your request, you have the right to ask for an internal review. Internal review requests should be submitted within two months of the date of this response; and can be addressed to this email address: info@mhra.gov.uk. Please remember to quote the reference number above in any future communications.
Yours sincerely,
FOI Team,
Vigilance and Risk Management of Medicines Division
The MHRA information supplied in response to your request is subject to Crown copyright. The FOIA only entitles you to access to MHRA information. For information on the reproduction or re-use of MHRA information, please visit https://www.gov.uk/government/publications/reproduce-or-re-use-mhra-information/reproduce-or-re-use-mhra-information
If you have a query about this email, please contact us. If you are unhappy with our decision, you may ask for it to be reviewed. That review will be undertaken by a senior member of the Agency who has not previously been involved in your request. If you wish to pursue that option please write to the Communications Directorate, 4-T, Medicines and Healthcare products Regulatory Agency, (via this email address). After that, if you remain dissatisfied, you may ask the Information Commissioner at:
The Information Commissioner’s Office
Wycliffe House
Water Lane
Wilmslow
Cheshire
SK9 5AF
Copyright notice
The information supplied in response to your request is the copyright of MHRA and/or a third party or parties and has been supplied for your personal use only. You may not sell, resell or otherwise use any information provided without prior agreement from the copyright holder.